Ferring Leapfrogs Into Late-Stage Microbiome Race With Rebiotix Buy

The Swiss specialty drug company gains a Phase III microbiome product for the prevention of recurrent Clostridium difficile infection and a broader platform for Microbiota Restoration Therapy.

Handshake of businessmen

Ferring Pharmaceuticals AS is taking a big leap into the forefront of the microbiome drug development space with the proposed acquisition of Rebiotix Inc.. The Swiss specialty pharma announced plans to buy Roseville, Minn.-based Rebiotix April 5 for an undisclosed sum, gaining a Phase III treatment for recurrent Clostridium difficile infection (CDI) that is a contender to be the first approved human microbiome product.

Rebiotix's RBX2660 is in Phase III testing for the prevention of recurrent CDI, and the company also has a pipeline...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.